scholarly journals Type III Neuregulin-1 Is Required for Normal Sensorimotor Gating, Memory-Related Behaviors, and Corticostriatal Circuit Components

2008 ◽  
Vol 28 (27) ◽  
pp. 6872-6883 ◽  
Author(s):  
Y.-J. J. Chen ◽  
M. A. Johnson ◽  
M. D. Lieberman ◽  
R. E. Goodchild ◽  
S. Schobel ◽  
...  
2020 ◽  
Vol 35 (1) ◽  
pp. 50-64
Author(s):  
Rose Chesworth ◽  
Rossana Rosa-Porto ◽  
Sofia Yao ◽  
Tim Karl

Background: Gene–environment interactions contribute to schizophrenia aetiology. Neuregulin 1 is a well-established genetic risk factor for schizophrenia, and elevated expression of type III neuregulin 1 mRNA in the dorsolateral prefrontal cortex is observed in patients with a core risk haplotype. A mouse model of type III Nrg1 overexpression ( Nrg1 III tg) possesses face and construct validity for schizophrenia; however, the sensitivity of these transgenic mice to environmental risk factors relevant to schizophrenia is unknown. Aims: To determine sensitivity of Nrg1 III tg mice to the psychostimulant methamphetamine (METH) in schizophrenia and addiction-relevant behavioural tests. Methods: We examined behavioural responses of adult male and female Nrg1 III tg mice METH (1–3 mg/kg) in schizophrenia-relevant paradigms (drug-induced locomotion, sensorimotor gating) and drug reward (conditioned place preference). Results: Male Nrg1 III tg mice were less sensitive to METH-induced stereotypies, yet showed a greater negative impact of METH on prepulse inhibition compared with wild type-like males. In contrast, female Nrg1 III tg mice were less sensitive to METH-induced locomotion than wild type-like females, while sensorimotor gating was similarly impaired by METH between the genotypes. There were no genotype differences for METH reward, or anxiety-like and exploratory behaviours. Conclusions: These results indicate that overexpression of Nrg1 type III modulates schizophrenia-relevant behaviours, and may help to explain increased sensitivity to the psychoactive effects of METH in patients with schizophrenia.


2018 ◽  
Vol 28 (6) ◽  
pp. 992-1006 ◽  
Author(s):  
Cristina Scapin ◽  
Cinzia Ferri ◽  
Emanuela Pettinato ◽  
Desiree Zambroni ◽  
Francesca Bianchi ◽  
...  

PLoS ONE ◽  
2011 ◽  
Vol 6 (12) ◽  
pp. e28692 ◽  
Author(s):  
Stephan Heermann ◽  
Julia Schmücker ◽  
Ursula Hinz ◽  
Michael Rickmann ◽  
Tilmann Unterbarnscheidt ◽  
...  

PLoS Genetics ◽  
2019 ◽  
Vol 15 (3) ◽  
pp. e1007857 ◽  
Author(s):  
Yun Liu ◽  
Yoshie Sugiura ◽  
Fujun Chen ◽  
Kuo-Fen Lee ◽  
Qiaohong Ye ◽  
...  

2018 ◽  
Author(s):  
Belin Sophie ◽  
Francesca Ornaghi ◽  
Ghjuvan'Ghjacumu Shackleford ◽  
Jie Wang ◽  
Cristina Scapin ◽  
...  

Myelin sheath thickness is precisely regulated and essential for rapid propagation of action potentials along myelinated axons. In the peripheral nervous system, extrinsic signals from the axonal protein neuregulin 1 type III regulate Schwann cell fate and myelination. Here we ask if modulating neuregulin 1 type III levels in neurons would restore myelination in a model of congenital hypomyelinating neuropathy (CHN). Using a mouse model of CHN, we rescued the myelination defects by early overexpression of neuregulin 1 type III. Surprisingly, the rescue was independent from the upregulation of Egr2 or essential myelin genes. Rather, we observed the activation of MAPK/ERK and other myelin genes such as peripheral myelin protein 2 (Pmp2) and oligodendrocyte myelin glycoprotein (Omg). We also confirmed that the permanent activation of MAPK/ERK in Schwann cells has detrimental effects on myelination. Our findings demonstrate that the modulation of axon-to-glial neuregulin 1 type III signaling has beneficial effects and restores myelination defects during development in a model of CHN.


2009 ◽  
Vol 66 (6) ◽  
pp. 614-620 ◽  
Author(s):  
Boris B. Quednow ◽  
Anne Schmechtig ◽  
Ulrich Ettinger ◽  
Nadine Petrovsky ◽  
David A. Collier ◽  
...  

2009 ◽  
Vol 331 (2) ◽  
pp. 473 ◽  
Author(s):  
Julie R. Perlin ◽  
William S. Talbot

Sign in / Sign up

Export Citation Format

Share Document